(a) RCCA-1 having a molecular weight of about 53 kD and a pI of about 9.30;

(b) RCCA-2 having a molecular weight of about 32 kD and a pI of about 6.95;

(c) RCCA-3 having a molecular weight of about 27 kD and a pI of about 6.50;

(d) RCCA-4 having a molecular weight of about 20 kD and a pI of about 5.25; and

(e) RCCA-5 having a molecular weight of about 15 kD and a pI of about 6.00 or an immunogenic fragment thereof.

22.　　(Thrice amended)　A method for detecting a cell proliferative disorder in a human subject, comprising contacting a cellular component from said subject with said antibody of claim 15, which binds to a cellular component associated with a cell proliferative disorder, and detecting whether or not the antibody binds to the cellular component.

In addition, please insert the following new claims:

50.　　(New)　An antibody directed against a renal nuclear matrix protein or an immunogenic fragment thereof that is present in normal human renal cells but absent in cancerous human renal cells, wherein said protein is RCNL-1 having a molecular weight of about 103 kD and a pI of about 8.30 or an immunogenic fragment thereof.

51.　　(New)　A method for detecting a cell proliferative disorder in a human subject, comprising contacting a cellular component from said subject with said antibody of claim 50, which binds to a cellular component associated with a cell proliferative disorder, and detecting whether or not the antibody binds to the cellular component.

52.　　(New)　The method of claim 51, wherein said antibody is polyclonal.

53.　　(New)　The method of claim 51, wherein said antibody is monoclonal.

54.　　(New)　The method of claim 51, wherein said antibody is detectably labeled.

55.　　(New)　The method of claim 54, wherein said label is selected from the group

002.831289.1